Journey Medical Corp (DERM) Announces Settlement Agreements Pertaining to QBREXZA, AMZEEQ and ZILXI Patent Exclusivity

Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Journey Medical and Padagis US LLC (“Padagis”) entered into a settlement agreement pertaining to the patents protecting QBREXZA®, the first and only prescription cloth towelette for the treatment of primary axillary hyperhidrosis, AMZEEQ®, the first and only topical minocycline product for the treatment of acne, and ZILXI®, the first and only topical minocycline product for the treatment of rosacea. Under terms of the paragraph IV settlement agreements, Padagis will not be allowed to launch generic versions of QBREXZA, AMZEEQ and ZILXI until August 15, 2030, July 1, 2031 and April 1, 2027, respectively.

Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer, said, “These settlement agreements are an important step for Journey Medical, as they assist with solidifying our exclusivity and provide a clear pathway for years to come allowing us to grow the sales of our three newest products, QBREXZA, AMZEEQ and ZILXI. We believe in and will continue to enforce the intellectual property rights of our products. We believe that these settlements are beneficial to our company and shareholders, as well as prescribing physicians and their patients who depend on our novel products for treatment.”

You May Also Be Interested In

• Boeing (BA) Statement on U.S. Air Force Collaborative Combat Aircraft Announcement
• Splash Beverage Group Inc. (SBEV) Appoints Julius Ivancsits as CFO
• ADT Corp. (ADT) Appoints Jeffrey A. Likosar as Permanent CFO